The Canadian government had entered into a supply deal with the company last year for supply of its COVID vaccine for 2022 and 2023, with the contract allowing access to new vaccine adaptations.

Moderna and the Canada have agreed to convert six million doses of the company's COVID-19 vaccine, which targets the original virus, to an Omicron-containing bivalent vaccine.